As a CRO specialising in psychedelics, we're currently engaged in nine trials encompassing a variety of drugs and therapy modalities, ranging from intensive therapy sessions to minimal psychological support. Broadly, these trials fall into two approaches: one aims to maximise efficacy by integrating therapy with the drug, while the other seeks to isolate the drug's effects by minimising therapy. Through these trials, we can discern what approaches yield favourable results and which do not.

Discover the latest strides in the realm of Treatment Resistant Depression (TRD) research in our latest blog. Join Dr. Iain Jordan, our Clinical Director, as he provides a comprehensive overview, delving into discussions on current treatments and unveiling the cutting-edge clinical research underway at Clerkenwell Health.

In recent years, significant strides have been made in the medical field regarding treatments for post-traumatic stress disorder (PTSD), notably in the use of entactogens like MDMA (commonly known as ecstasy) and methylone to aid therapy. For individuals whose lives have been profoundly impacted by PTSD, these advancements offer additional options, especially when traditional treatments like psychotherapy and medication are not enough.   

In most countries, clinical trials are the only way to receive psychedelic therapy in a medical setting. If you’re interested in participating in one but not sure how, this guide will walk you through what you need to know.